JP2012107057A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012107057A5 JP2012107057A5 JP2012040330A JP2012040330A JP2012107057A5 JP 2012107057 A5 JP2012107057 A5 JP 2012107057A5 JP 2012040330 A JP2012040330 A JP 2012040330A JP 2012040330 A JP2012040330 A JP 2012040330A JP 2012107057 A5 JP2012107057 A5 JP 2012107057A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- following formula
- salt
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 4
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68172205P | 2005-05-17 | 2005-05-17 | |
| US68172305P | 2005-05-17 | 2005-05-17 | |
| US68177205P | 2005-05-17 | 2005-05-17 | |
| US68168405P | 2005-05-17 | 2005-05-17 | |
| US60/681,772 | 2005-05-17 | ||
| US60/681,723 | 2005-05-17 | ||
| US60/681,722 | 2005-05-17 | ||
| US60/681,684 | 2005-05-17 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512519A Division JP5794721B2 (ja) | 2005-05-17 | 2006-05-17 | 眼障害の治療のための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012107057A JP2012107057A (ja) | 2012-06-07 |
| JP2012107057A5 true JP2012107057A5 (enExample) | 2012-10-25 |
Family
ID=37431594
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512519A Active JP5794721B2 (ja) | 2005-05-17 | 2006-05-17 | 眼障害の治療のための組成物および方法 |
| JP2012040330A Pending JP2012107057A (ja) | 2005-05-17 | 2012-02-27 | 眼障害の治療のための組成物および方法 |
| JP2012225028A Active JP6288907B2 (ja) | 2005-05-17 | 2012-10-10 | 眼障害の治療のための組成物および方法 |
| JP2015137500A Withdrawn JP2015187165A (ja) | 2005-05-17 | 2015-07-09 | 眼障害の治療のための組成物および方法 |
| JP2017099005A Withdrawn JP2017141297A (ja) | 2005-05-17 | 2017-05-18 | 眼障害の治療のための組成物および方法 |
| JP2019022433A Active JP6816180B2 (ja) | 2005-05-17 | 2019-02-12 | 眼障害の治療のための組成物および方法 |
| JP2020030710A Pending JP2020079312A (ja) | 2005-05-17 | 2020-02-26 | 眼障害の治療のための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512519A Active JP5794721B2 (ja) | 2005-05-17 | 2006-05-17 | 眼障害の治療のための組成物および方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012225028A Active JP6288907B2 (ja) | 2005-05-17 | 2012-10-10 | 眼障害の治療のための組成物および方法 |
| JP2015137500A Withdrawn JP2015187165A (ja) | 2005-05-17 | 2015-07-09 | 眼障害の治療のための組成物および方法 |
| JP2017099005A Withdrawn JP2017141297A (ja) | 2005-05-17 | 2017-05-18 | 眼障害の治療のための組成物および方法 |
| JP2019022433A Active JP6816180B2 (ja) | 2005-05-17 | 2019-02-12 | 眼障害の治療のための組成物および方法 |
| JP2020030710A Pending JP2020079312A (ja) | 2005-05-17 | 2020-02-26 | 眼障害の治療のための組成物および方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (34) | US8168655B2 (enExample) |
| EP (3) | EP2444079B1 (enExample) |
| JP (7) | JP5794721B2 (enExample) |
| CN (2) | CN102617557A (enExample) |
| AU (1) | AU2006247136C1 (enExample) |
| CA (3) | CA2960117C (enExample) |
| CY (1) | CY1118660T1 (enExample) |
| DK (2) | DK1881823T3 (enExample) |
| ES (2) | ES2614080T3 (enExample) |
| HU (1) | HUE031979T2 (enExample) |
| LT (1) | LT2444079T (enExample) |
| PL (2) | PL2444079T3 (enExample) |
| PT (2) | PT1881823E (enExample) |
| SI (2) | SI1881823T1 (enExample) |
| WO (1) | WO2006125119A1 (enExample) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105820160B (zh) | 2003-11-05 | 2019-02-12 | 萨可德生物科学公司 | 细胞粘着调节剂 |
| ES2402469T3 (es) | 2005-04-13 | 2013-05-06 | Astex Therapeutics Limited | Derivados de hidroxibenzamida y sus usos como inhibidores de la Hsp90 |
| CN102617557A (zh) * | 2005-05-17 | 2012-08-01 | 萨可德生物科学公司 | 治疗眼病的组合物和方法 |
| US7202209B2 (en) * | 2005-07-13 | 2007-04-10 | Allergan, Inc. | Cyclosporin compositions |
| US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
| WO2008044041A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| EP2073804B1 (en) | 2006-10-12 | 2017-09-13 | Astex Therapeutics Limited | Hydroxy-substituted benzoic acid amide compounds for use in the treatment of pain |
| GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| JP5528807B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| KR100930467B1 (ko) * | 2007-06-07 | 2009-12-08 | 동아제약주식회사 | 점액분비를 촉진시키는 3',4',5-트리메톡시 플라본 유도체화합물, 그의 제조방법 및 약학적 용도 |
| EP2209371B1 (en) * | 2007-10-19 | 2017-01-04 | SARcode Bioscience Inc. | Compositions and methods for treatment of diabetic retinopathy |
| JP2011518155A (ja) * | 2008-04-15 | 2011-06-23 | サーコード コーポレイション | 免疫関連障害の局所治療に使用するためのエアゾール化ｌｆａ−１アンタゴニスト |
| US8080562B2 (en) | 2008-04-15 | 2011-12-20 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
| EP2276508A4 (en) * | 2008-04-15 | 2011-12-28 | Sarcode Bioscience Inc | ADMINISTRATION OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM |
| CN102056485A (zh) * | 2008-04-15 | 2011-05-11 | 萨可德公司 | 用于局部治疗免疫相关疾病的局部lfa-1拮抗剂 |
| CN105943534A (zh) * | 2008-04-15 | 2016-09-21 | 萨可德生物科学公司 | 用于局部治疗免疫相关疾病的局部lfa-1拮抗剂 |
| JP5216912B2 (ja) * | 2008-04-29 | 2013-06-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ１受容体拮抗薬としてのインダゾール化合物 |
| US8293917B2 (en) | 2008-05-06 | 2012-10-23 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as CCR1 antagonists |
| CN105664136A (zh) * | 2008-05-07 | 2016-06-15 | 加利福尼亚大学董事会 | 眼表润滑的治疗性补充和富集 |
| US8506944B2 (en) | 2008-05-07 | 2013-08-13 | The Regents Of The University Of California | Replenishment and enrichment of ocular surface lubrication |
| US7879873B2 (en) * | 2008-09-26 | 2011-02-01 | Boehringer Ingelheim International Gmbh | Azaindazole compounds as CCR1 receptor antagonists |
| KR20120034666A (ko) | 2009-05-22 | 2012-04-12 | 엑셀리시스, 인코포레이티드 | 증식성 질환에 대한 벤족사제핀 기반 ｐ１３ｋ／ｍｔ０ｒ의 억제제 |
| SI2464645T1 (sl) | 2009-07-27 | 2017-10-30 | Gilead Sciences, Inc. | Zlite heterociklične spojine kot ionsko kanalni modulatorji |
| US8378105B2 (en) * | 2009-10-21 | 2013-02-19 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
| CN102666526A (zh) | 2009-10-21 | 2012-09-12 | 贝林格尔.英格海姆国际有限公司 | 作为ccr1受体拮抗剂的吲唑和吡唑并吡啶化合物 |
| US8927550B2 (en) | 2009-10-27 | 2015-01-06 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as CCR1 receptor antagonists |
| EA201200820A1 (ru) * | 2009-12-08 | 2013-01-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ синтеза промежуточных продуктов, применимых для получения замещенных индазолов и азаиндазолов |
| JP5793182B2 (ja) | 2010-04-30 | 2015-10-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ１受容体アンタゴニストとしてのアザインダゾールアミド化合物 |
| MX2012015096A (es) | 2010-07-02 | 2013-05-28 | Gilead Sciences Inc | Compuestos heterociclicos fusionados como moduladores del canal ion. |
| US8546442B2 (en) | 2010-12-23 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Pyrazolopiperidine compounds as CCR1 receptor antagonists |
| US9962361B2 (en) | 2011-01-03 | 2018-05-08 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
| US8933119B2 (en) | 2011-01-03 | 2015-01-13 | The William M. Yarbrough Foundation | Method for treating phytophotodermatitis |
| US10647668B2 (en) | 2011-01-03 | 2020-05-12 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactant and associated method of use |
| US10640464B2 (en) | 2011-01-03 | 2020-05-05 | The William M. Yarbrough Foundation | Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases |
| US11279674B2 (en) | 2011-01-03 | 2022-03-22 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactant and associated method of use |
| US10273205B2 (en) | 2011-01-03 | 2019-04-30 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms |
| US10308599B2 (en) | 2011-01-03 | 2019-06-04 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
| US11407713B2 (en) | 2011-01-03 | 2022-08-09 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
| US8865765B2 (en) | 2011-01-12 | 2014-10-21 | The William M. Yarbrough Foundation | Method for treating eczema |
| US9532969B2 (en) | 2011-02-08 | 2017-01-03 | The William M. Yarbrough Foundation | Method for treating psoriasis |
| NZ716420A (en) | 2011-05-10 | 2017-05-26 | Gilead Sciences Inc | Fused heterocyclic compounds as sodium channel modulators |
| TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (enExample) | 2011-07-01 | 2018-04-28 | ||
| CA2857127A1 (en) * | 2012-01-27 | 2013-08-01 | F. Hoffmann-La Roche Ag | Integrin antagonist conjugates for targeted delivery to cells expressing lfa-1 |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| AU2013295706A1 (en) | 2012-07-25 | 2015-02-19 | Sarcode Bioscience Inc. | LFA-1 inhibitor and polymorph thereof |
| US10335387B2 (en) | 2012-07-26 | 2019-07-02 | The William M. Yarbrough Foundation | Method for treating infectious diseases with isothiocyanate functional compounds |
| US9949943B2 (en) | 2012-07-26 | 2018-04-24 | The William M. Yarbrough Foundation | Method for treating neurodegenerative diseases |
| US10434082B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms |
| US10441561B2 (en) | 2012-07-26 | 2019-10-15 | The William M. Yanbrough Foundation | Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer |
| US10080734B2 (en) | 2012-07-26 | 2018-09-25 | The William M. Yarbrough Foundation | Method for treating autism and other neurodevelopmental disorders |
| US10434081B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Inhibitors of macrophage migration inhibitory factor |
| WO2014018874A1 (en) | 2012-07-26 | 2014-01-30 | The William M. Yarbrough Foundation | Method for treating skin cancer |
| US9839621B2 (en) | 2012-07-26 | 2017-12-12 | The William M. Yarbrough Foundation | Method for treating bladder cancer |
| WO2014092958A1 (en) * | 2012-12-10 | 2014-06-19 | Molecular Targeting Technologies, Inc. | Compositions and methods of diagnosing ocular diseases |
| US11058677B2 (en) * | 2012-12-19 | 2021-07-13 | Novartis Ag | LFA-1 inhibitor formulations |
| CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
| CN113230021A (zh) | 2015-01-12 | 2021-08-10 | 科达莱昂治疗公司 | 微滴递送设备和方法 |
| CA2989522C (en) * | 2015-07-08 | 2022-10-18 | Achim Hans-Peter Krauss | Pharmaceutical compositions and methods for treating ocular inflammatory conditions |
| CN106995439B (zh) * | 2016-01-26 | 2019-09-20 | 镇江圣安医药有限公司 | 氘取代3-(甲磺酰基)-l-苯丙氨酸衍生物及其药物组合物、药物制剂和用途 |
| JP2019507193A (ja) | 2016-03-04 | 2019-03-14 | ジェームズ・エム・ライナーソン | 細菌のバイオフィルム形成を阻止又は妨害することによって眼障害を治療する方法 |
| SG11201901137UA (en) | 2016-08-12 | 2019-03-28 | Silk Technologies Ltd | Silk-derived protein for treating inflammation |
| WO2018035469A1 (en) | 2016-08-19 | 2018-02-22 | Akrivista, LLC | Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye |
| US9981041B2 (en) * | 2016-08-23 | 2018-05-29 | Ira Jason Salzman | Ophthalmic lubricating spray |
| AU2017324262B2 (en) * | 2016-09-07 | 2023-06-22 | Glia, Llc | Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves |
| CA3039106A1 (en) | 2017-01-20 | 2018-07-26 | Kedalion Therapeutics, Inc. | Piezoelectric fluid dispenser |
| CN109134533B (zh) * | 2017-06-27 | 2020-08-11 | 维眸生物科技（上海）有限公司 | 一种含磷化合物及其制备和应用 |
| ES2876292T3 (es) | 2017-07-24 | 2021-11-12 | Interquim Sa | Procedimiento de preparación y purificación del antagonista de LFA-1 lifitegrast |
| JP7311160B2 (ja) | 2017-08-18 | 2023-07-19 | アクリビスタ エルエルシー | ドライアイ症候群を診断及び処置する方法及びヒトの眼を処置するための組成物 |
| IL273428B2 (en) | 2017-09-22 | 2023-09-01 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
| CA3080677A1 (en) | 2017-11-06 | 2019-05-09 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
| WO2019097547A1 (en) | 2017-11-15 | 2019-05-23 | Cipla Limited | An improved process for the preparation of lifitegrast or salts thereof |
| WO2019096996A1 (en) | 2017-11-17 | 2019-05-23 | Medichem, S.A. | A process to obtain a tetrahydroisoquinoline derivative |
| SMT202400203T1 (it) | 2017-11-24 | 2024-07-09 | Jubilant Episcribe Llc | Composti eterociclici come inibitori di prmt5 |
| WO2019113483A1 (en) | 2017-12-08 | 2019-06-13 | Kedalion Therapeutics, Inc. | Fluid delivery alignment system |
| MX2020009517A (es) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1. |
| US12350194B1 (en) | 2018-04-12 | 2025-07-08 | Bausch + Lomb Ireland Limited | Topical ocular delivery of fluids with controlled mass dosing and wireless communication |
| US20190314197A1 (en) | 2018-04-12 | 2019-10-17 | Kedalion Therapeutics, Inc. | Topical Ocular Delivery Methods and Devices for Use in the Same |
| PE20201448A1 (es) | 2018-04-18 | 2020-12-10 | Constellation Pharmaceuticals Inc | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos |
| CN120097995A (zh) | 2018-05-21 | 2025-06-06 | 星座制药公司 | 甲基修饰酶的调节剂、其组合物和用途 |
| KR102827233B1 (ko) | 2018-07-03 | 2025-06-30 | 보슈 롬 아일랜드 리미티드 | 국소 안구 전달 디바이스들 및 이를 사용하기 위한 방법들 |
| US11166910B2 (en) * | 2019-01-25 | 2021-11-09 | Nordiccan A/S | Cannabinoid chewing gum with sugar alcohols |
| US11679028B2 (en) | 2019-03-06 | 2023-06-20 | Novartis Ag | Multi-dose ocular fluid delivery system |
| US12097145B2 (en) | 2019-03-06 | 2024-09-24 | Bausch + Lomb Ireland Limited | Vented multi-dose ocular fluid delivery system |
| CN114025759A (zh) | 2019-04-18 | 2022-02-08 | 阿祖拉眼科有限公司 | 用于治疗眼病的化合物和方法 |
| US20200345805A1 (en) * | 2019-04-22 | 2020-11-05 | Allegro Ophthalmics, Llc | Compositions and methods useable for treatment of dry eye |
| WO2021016548A1 (en) * | 2019-07-25 | 2021-01-28 | North Carolina State University | Polyiodide binding compounds and methods of use thereof |
| US12496218B1 (en) | 2019-11-12 | 2025-12-16 | Bausch + Lomb Ireland Limited | Fractionated topical ocular drug delivery methods and devices for use in the same |
| US12290472B2 (en) | 2020-04-17 | 2025-05-06 | Bausch + Lomb Ireland Limited | Hydrodynamically actuated preservative free dispensing system |
| WO2021212038A1 (en) | 2020-04-17 | 2021-10-21 | Kedalion Therapeutics, Inc. | Hydrodynamically actuated preservative free dispensing system having a collapsible liquid reservoir |
| US11938057B2 (en) | 2020-04-17 | 2024-03-26 | Bausch + Lomb Ireland Limited | Hydrodynamically actuated preservative free dispensing system |
| KR20230034940A (ko) | 2020-04-17 | 2023-03-10 | 노파르티스 아게 | 유체역학적으로 작동되는 방부제 없는 분배 시스템 |
| US11459351B1 (en) | 2021-04-05 | 2022-10-04 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| US11213551B1 (en) | 2021-04-05 | 2022-01-04 | Korb Research, Llc. | Ocular treatment compositions and methods of use thereof |
| CN115707698A (zh) * | 2021-08-18 | 2023-02-21 | 辽宁何氏医学院 | 5,7-二氯-1,2,3,4-四氢异喹啉-6-甲酰胺类化合物及其制备方法和应用 |
| EP4507786A2 (en) * | 2022-04-13 | 2025-02-19 | The Regents Of The University Of California | Methods of producing plasma or serum and uses thereof |
| JP2024042677A (ja) * | 2022-09-15 | 2024-03-28 | 日油株式会社 | コンタクトレンズ用溶液 |
| WO2024215778A1 (en) * | 2023-04-10 | 2024-10-17 | Insitu Biologics, Inc. | Sustained release stable emulsion pharmaceutical formulations |
| WO2025223511A1 (zh) * | 2024-04-25 | 2025-10-30 | 上海翊石医药科技有限公司 | 一类苯甲酰基甘氨酸衍生物及其制备方法和应用 |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US744A (en) * | 1838-05-17 | Mode of cutting off steam in steam-engines | ||
| US423439A (en) * | 1890-03-18 | Stove-pipe guard and register | ||
| GB138135A (en) * | 1918-08-13 | 1920-02-05 | Hugh William Gabbett Fairfax | Improvements in automatic firearms |
| US1680610A (en) * | 1926-09-16 | 1928-08-14 | Mary Y Harmon | Batik-frame support |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3876444A (en) * | 1970-04-24 | 1975-04-08 | Gen Electric | Method of treating high strength carbon fibers |
| IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4668506A (en) | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
| US4931279A (en) | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
| US4713244A (en) * | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) * | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| GB2209937B (en) * | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| EP0314863B1 (en) | 1987-11-02 | 1994-12-07 | Baylor College Of Medicine | Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation |
| DE68907066T2 (de) * | 1988-01-29 | 1993-12-16 | Koken Kk | Verbesserte Formulierungen mit kontrollierter Abgabe. |
| DE3802996A1 (de) | 1988-02-02 | 1989-08-10 | Cassella Ag | Verwendung von 2-oxo-pyrrolidin-1-acetamid zur bestimmung der glomerulaeren filtrationsrate beim menschen |
| US5424399A (en) * | 1988-06-28 | 1995-06-13 | The Children's Medical Center Corporation | Human CR3α/β heterodimers |
| ATE123810T1 (de) | 1988-08-23 | 1995-06-15 | Dana Farber Cancer Inst Inc | Alpha-subeinheit des lfa-1-leukocyt-adhäsions- rezeptors. |
| DE68929096T2 (de) | 1988-09-01 | 2000-05-11 | Bayer Corp., Pittsburgh | Menschliches Rhinovirusrezeptorprotein, das die Virusinfektionsanfälligkeit hemmt |
| AU4412889A (en) | 1988-09-28 | 1990-04-18 | Dana-Farber Cancer Institute | Intercellular adhesion molecules, and their binding ligands |
| US5149780A (en) * | 1988-10-03 | 1992-09-22 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
| EP0462184A4 (en) | 1989-03-09 | 1992-01-08 | Dana Farber Cancer Institute | Method of treating viral infections using lfa-1 |
| AU5553290A (en) | 1989-04-28 | 1990-11-29 | Baylor College Of Medicine | Dissemination of hiv-1 infected cells |
| CH679207A5 (enExample) | 1989-07-28 | 1992-01-15 | Debiopharm Sa | |
| WO1991019511A1 (en) | 1990-06-18 | 1991-12-26 | The General Hospital Corporation | CONTROLLING CELLULAR IMMUNE/INFLAMMATORY RESPONSES WITH β2 INTEGRINS |
| CA2046830C (en) | 1990-07-19 | 1999-12-14 | Patrick P. Deluca | Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer |
| US5318965A (en) | 1990-08-24 | 1994-06-07 | Abbott Laboratories | Quinobenzoxazine, antineoplastic agents |
| EP0546077A1 (en) | 1990-08-27 | 1993-06-16 | Chiron Corporation | Cd18 peptide medicaments for the treatment of disease |
| JP2995860B2 (ja) | 1990-11-27 | 1999-12-27 | 味の素株式会社 | 新規ペプチド |
| US5288854A (en) * | 1990-11-28 | 1994-02-22 | Center For Blood Research, Inc. | Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1 |
| CH683149A5 (fr) * | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
| EP0610290B1 (en) * | 1991-10-04 | 1999-05-26 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Manufacture of a medicament for treatment of ocular inflammation by blockage of cell adhesion molecules |
| GB9211268D0 (en) | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| US5298492A (en) * | 1992-08-04 | 1994-03-29 | Schering Corporation | Diamino acid derivatives as antihypertensives |
| DK0656789T3 (da) * | 1992-08-21 | 1998-08-24 | Genentech Inc | Fremgangsmåde til behandling af en LFA-1-medieretforstyrrelse. |
| WO1994011400A1 (en) | 1992-11-18 | 1994-05-26 | Helsinki University Licensing Ltd. Oy | Peptides from human icam-2 and from human icam-1 and their analogs for use in therapy and diagnosis |
| US5672659A (en) * | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| RU2146128C1 (ru) | 1993-01-06 | 2000-03-10 | Кинертон Лимитед | Ионный конъюгат с длительным периодом высвобождения пептида, способ синтезирования ионного конъюгата, способ синтезирования микрочастиц |
| US5424289A (en) * | 1993-07-30 | 1995-06-13 | Alza Corporation | Solid formulations of therapeutic proteins for gastrointestinal delivery |
| US5397791A (en) * | 1993-08-09 | 1995-03-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| PT656348E (pt) * | 1993-12-03 | 2000-10-31 | Hoffmann La Roche | Derivados do acido acetico como medicamentos |
| US5470953A (en) * | 1993-12-23 | 1995-11-28 | Icos Corporation | Human β2 integrin α subunit |
| JPH09512021A (ja) | 1994-04-19 | 1997-12-02 | ザ ユニバーシティ オブ カンサス | Ｉｃａｍ−１／ｌｆａ−１ 短鎖ペプチドおよび該ペプチドの使用方法 |
| US5849327A (en) | 1994-07-29 | 1998-12-15 | Advanced Polymer Systems, Inc. | Delivery of drugs to the lower gastrointestinal tract |
| US5585359A (en) | 1994-09-29 | 1996-12-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| EP0710657B1 (de) * | 1994-11-02 | 1998-08-26 | MERCK PATENT GmbH | Adhäsionsrezeptor-Antagonisten |
| US5612052A (en) * | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
| CA2220055C (en) * | 1995-05-08 | 2001-04-24 | Pfizer Inc. | Dipeptides which promote release of growth hormone |
| US5877224A (en) * | 1995-07-28 | 1999-03-02 | Rutgers, The State University Of New Jersey | Polymeric drug formulations |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
| ES2234014T3 (es) | 1996-04-23 | 2005-06-16 | Ipsen Manufacturing Ireland Limited | Polimeros polilacticos acidos. |
| HRP970493A2 (en) | 1996-09-23 | 1998-08-31 | Wienman E. Phlips | Oral delayed immediate release medical formulation and method for preparing the same |
| CA2217134A1 (en) * | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| US6130231A (en) * | 1996-11-27 | 2000-10-10 | Dupont Pharmaceuticals | Integrin receptor antagonists |
| US5968895A (en) | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| US5893985A (en) * | 1997-03-14 | 1999-04-13 | The Lincoln Electric Company | Plasma arc torch |
| AR012443A1 (es) | 1997-04-16 | 2000-10-18 | Uriach & Cia Sa J | Nuevas carboxamidas como inhibidores de la agregacion plaquetaria, procedimiento para su preparacion, composiciones farmaceuticas que loscontienen y uso de los mismos en la manufactura de medicamentos |
| AU737735B2 (en) | 1997-08-28 | 2001-08-30 | Novartis Ag | Lymphocyte function antigen-1 antagonists |
| WO1999049856A2 (en) | 1998-03-27 | 1999-10-07 | Genentech, Inc. | Antagonists for treatment of cd11/cd18 adhesion receptor mediated disorders |
| DK1037627T3 (da) * | 1998-07-14 | 2001-10-01 | Alcon Lab Inc | Anvendelse af 11-(3-dimethylamino-propyliden)-6, 11-dihydrodibenz[b,e]oxepin-2-eddikesyre og af farmaceutisk acceptable salte deraf til fremstillingen af et lægemiddel til behandlingen af non-allergiske... |
| US6331640B1 (en) * | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
| IL143356A0 (en) | 1998-11-27 | 2002-04-21 | Takada Kanji | An oral formulation for gastrointestinal drug delivery |
| IT1304152B1 (it) | 1998-12-10 | 2001-03-08 | Mediolanum Farmaceutici Srl | Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato |
| US6670321B1 (en) * | 1998-12-30 | 2003-12-30 | The Children's Medical Center Corporation | Prevention and treatment for retinal ischemia and edema |
| ATE330631T1 (de) * | 1999-01-05 | 2006-07-15 | Univ Southern Australia | Antikörperfragmente zur lokalen behandlung von augenerkrankungen |
| AU2847200A (en) | 1999-01-27 | 2000-08-18 | G.D. Searle & Co. | Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors |
| EP1028114A1 (en) * | 1999-02-13 | 2000-08-16 | Aventis Pharma Deutschland GmbH | Novel guanidine derivatives as inhibitors of cell adhesion |
| AU776645B2 (en) * | 1999-03-31 | 2004-09-16 | Janssen Pharmaceutica N.V. | Pregelatinized starch in a controlled release formulation |
| WO2001001964A2 (en) | 1999-06-23 | 2001-01-11 | Sedum Laboratories, Inc. | Ionically formulated biomolecule microcarriers |
| MXPA02001699A (es) | 1999-08-18 | 2003-01-28 | Sod Conseils Rech Applic | Formulacion de liberacion sostenida de un peptido. |
| ECSP003707A (es) | 1999-10-13 | 2002-05-23 | Novartis Ag | Diazepanes |
| HK1049785A1 (zh) | 1999-10-22 | 2003-05-30 | Biogen, Inc. | Cd40:cd154结合阻断剂在治疗眼睛免疫并发症的用途 |
| US6294522B1 (en) * | 1999-12-03 | 2001-09-25 | Cv Therapeutics, Inc. | N6 heterocyclic 8-modified adenosine derivatives |
| US6605597B1 (en) * | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
| AU768324B2 (en) * | 1999-12-14 | 2003-12-11 | Genentech Inc. | TNF-alpha antagonist and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder |
| WO2001049311A1 (en) | 1999-12-31 | 2001-07-12 | Rutgers, The State University | Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release |
| US7521061B2 (en) | 1999-12-31 | 2009-04-21 | Rutgers, The State University Of New Jersey | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
| JP2003519164A (ja) | 1999-12-31 | 2003-06-17 | ルトガーズ、ザ ステイト ユニバーシティ | ポリマーマトリクスに基づく生理活性化合物徐放調節用医薬製剤 |
| US20030064105A1 (en) | 2000-08-25 | 2003-04-03 | Myung-Jin Kim | Lipophilic-coated microparticle containing a protein drug and formulation comprising same |
| US6630447B2 (en) | 2000-01-14 | 2003-10-07 | University Of New Mexico | Peptide inhibitors of LFA-1/ICAM-1 interaction |
| US6515124B2 (en) | 2000-02-09 | 2003-02-04 | Hoffman-La Roche Inc. | Dehydroamino acids |
| US6821986B2 (en) * | 2000-05-05 | 2004-11-23 | Societe De Conseils De Recherchet Et E'applications Scientifiques (S.C.R.A.S.) | Amino acid derivatives and their use as medicines |
| GB0011817D0 (en) | 2000-05-16 | 2000-07-05 | Pharmacia & Upjohn Spa | Antagonists of integrin receptors |
| NZ523445A (en) * | 2000-06-29 | 2004-10-29 | Abbott Lab | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| PE20020420A1 (es) | 2000-10-02 | 2002-06-27 | Novartis Ag | Derivados de diazacicloalcanodiona como antagonistas del antigeno asociado a la funcion del linfocito-1 (lfa-1) |
| GB0025208D0 (en) | 2000-10-13 | 2000-11-29 | Euro Celtique Sa | Delayed release pharmaceutical formulations |
| US6653478B2 (en) * | 2000-10-27 | 2003-11-25 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators |
| DE10055857A1 (de) | 2000-11-10 | 2002-08-22 | Creative Peptides Sweden Ab Dj | Neue pharmazeutische Depotformulierung |
| GB0028367D0 (en) * | 2000-11-21 | 2001-01-03 | Celltech Chiroscience Ltd | Chemical compounds |
| AU2002248142B2 (en) | 2000-11-28 | 2007-11-01 | Genentech, Inc. | LFA-1 antagonist compounds |
| WO2002050080A1 (en) | 2000-12-19 | 2002-06-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
| WO2002058672A2 (en) | 2001-01-26 | 2002-08-01 | Debio Recherche Pharmaceutique S.A. | Microparticles of biodegradable polymer encapsulating a biologically active substance |
| ES2275808T3 (es) * | 2001-02-06 | 2007-06-16 | Pfizer Products Inc. | Composiciones farmaceuticas para el tratamiento de trastornos del snc y otros trastornos. |
| US20030044406A1 (en) * | 2001-03-02 | 2003-03-06 | Christine Dingivan | Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents |
| AU2002258563A1 (en) | 2001-03-19 | 2002-10-03 | Praecis Pharmaceuticals Incorporated | Pharmaceutical formulations for sustained release |
| US6872382B1 (en) * | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
| MXPA03009660A (es) | 2001-06-06 | 2004-04-02 | Aventis Pharma Ltd | Tetrahidroisoquinolinas sustituidas para su uso en el tratamiento de enfermedades inflamatorias. |
| MXPA04006026A (es) | 2001-12-19 | 2005-03-31 | Alza Corp | Formulacion y forma de dosificacion para aumentar la biodisponibilidad oral de macromoleculas hidrofilitas. |
| WO2003075887A1 (en) | 2002-03-04 | 2003-09-18 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Sustained release drug formulations containing a carrier peptide |
| AU2003250482A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Phthalimide derivatives as matrix metalloproteinase inhibitors |
| MXPA05003063A (es) | 2002-09-20 | 2005-05-27 | Alcon Inc | Uso de inhibidores de la sintesis de citosina para el tratamiento de trastornos de ojos secos. |
| US7785578B2 (en) * | 2002-10-11 | 2010-08-31 | Aciont, Inc. | Non-invasive ocular drug delivery |
| JP2007501844A (ja) | 2003-08-08 | 2007-02-01 | トランス テック ファーマ，インコーポレイテッド | アリール及びヘテロアリール化合物、組成物並びに使用方法 |
| US7459472B2 (en) | 2003-08-08 | 2008-12-02 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| WO2005042710A1 (en) | 2003-10-28 | 2005-05-12 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of statin to kill ebv-transformed b cells |
| CN105820160B (zh) * | 2003-11-05 | 2019-02-12 | 萨可德生物科学公司 | 细胞粘着调节剂 |
| GT200500139A (es) | 2004-06-08 | 2005-07-25 | Metodo para la preparacion de acidos hidroxamicos | |
| CN102617557A (zh) * | 2005-05-17 | 2012-08-01 | 萨可德生物科学公司 | 治疗眼病的组合物和方法 |
| US7541420B2 (en) * | 2006-06-30 | 2009-06-02 | Sabic Innovative Plastics Ip B.V. | Method for making molded polycarbonate articles with improved color |
| JP4193895B2 (ja) | 2006-10-12 | 2008-12-10 | 横河電機株式会社 | 欠陥検査装置 |
| EP2209371B1 (en) * | 2007-10-19 | 2017-01-04 | SARcode Bioscience Inc. | Compositions and methods for treatment of diabetic retinopathy |
| EP2276508A4 (en) * | 2008-04-15 | 2011-12-28 | Sarcode Bioscience Inc | ADMINISTRATION OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM |
| US8080562B2 (en) | 2008-04-15 | 2011-12-20 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
| CN102056485A (zh) * | 2008-04-15 | 2011-05-11 | 萨可德公司 | 用于局部治疗免疫相关疾病的局部lfa-1拮抗剂 |
| US8337942B2 (en) * | 2009-08-28 | 2012-12-25 | Minsek David W | Light induced plating of metals on silicon photovoltaic cells |
| US8378105B2 (en) * | 2009-10-21 | 2013-02-19 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
| AU2013295706A1 (en) * | 2012-07-25 | 2015-02-19 | Sarcode Bioscience Inc. | LFA-1 inhibitor and polymorph thereof |
-
2006
- 2006-05-17 CN CN2012100314315A patent/CN102617557A/zh active Pending
- 2006-05-17 DK DK06770607.7T patent/DK1881823T3/en active
- 2006-05-17 CA CA2960117A patent/CA2960117C/en active Active
- 2006-05-17 PL PL11181066T patent/PL2444079T3/pl unknown
- 2006-05-17 EP EP11181066.9A patent/EP2444079B1/en active Active
- 2006-05-17 PT PT06770607T patent/PT1881823E/pt unknown
- 2006-05-17 LT LTEP11181066.9T patent/LT2444079T/lt unknown
- 2006-05-17 SI SI200631898T patent/SI1881823T1/sl unknown
- 2006-05-17 US US11/436,906 patent/US8168655B2/en active Active
- 2006-05-17 WO PCT/US2006/019327 patent/WO2006125119A1/en not_active Ceased
- 2006-05-17 HU HUE11181066A patent/HUE031979T2/en unknown
- 2006-05-17 EP EP06770607.7A patent/EP1881823B1/en active Active
- 2006-05-17 DK DK11181066.9T patent/DK2444079T3/en active
- 2006-05-17 CN CN2006800171884A patent/CN101175488B/zh not_active Ceased
- 2006-05-17 SI SI200632151A patent/SI2444079T1/sl unknown
- 2006-05-17 CA CA2985444A patent/CA2985444C/en active Active
- 2006-05-17 ES ES11181066.9T patent/ES2614080T3/es active Active
- 2006-05-17 CA CA2609053A patent/CA2609053C/en active Active
- 2006-05-17 EP EP16201157.1A patent/EP3195861A1/en not_active Withdrawn
- 2006-05-17 ES ES06770607T patent/ES2530780T3/es active Active
- 2006-05-17 AU AU2006247136A patent/AU2006247136C1/en active Active
- 2006-05-17 JP JP2008512519A patent/JP5794721B2/ja active Active
- 2006-05-17 PL PL06770607T patent/PL1881823T3/pl unknown
- 2006-05-17 PT PT111810669T patent/PT2444079T/pt unknown
-
2009
- 2009-07-23 US US12/508,311 patent/US20100092541A1/en not_active Abandoned
- 2009-07-23 US US12/508,367 patent/US8084047B2/en active Active
-
2011
- 2011-01-21 US US13/011,760 patent/US8771715B2/en active Active
- 2011-01-21 US US13/011,775 patent/US8758776B2/en active Active
-
2012
- 2012-02-16 US US13/398,542 patent/US8592450B2/en active Active
- 2012-02-27 JP JP2012040330A patent/JP2012107057A/ja active Pending
- 2012-10-10 JP JP2012225028A patent/JP6288907B2/ja active Active
-
2013
- 2013-08-08 US US13/962,440 patent/US20140099387A1/en not_active Abandoned
- 2013-08-08 US US13/962,369 patent/US20140073666A1/en not_active Abandoned
- 2013-10-03 US US14/045,131 patent/US9045457B2/en active Active
- 2013-10-03 US US14/045,159 patent/US10188641B2/en active Active
-
2014
- 2014-05-12 US US14/275,241 patent/US9051297B2/en active Active
- 2014-05-12 US US14/275,159 patent/US9045458B2/en active Active
-
2015
- 2015-01-30 US US14/610,401 patent/US20150140082A1/en not_active Abandoned
- 2015-01-30 US US14/609,998 patent/US20150140077A1/en not_active Abandoned
- 2015-01-30 US US14/609,795 patent/US20150216857A1/en not_active Abandoned
- 2015-01-30 US US14/609,770 patent/US20150140076A1/en not_active Abandoned
- 2015-01-30 US US14/610,464 patent/US20150174119A1/en not_active Abandoned
- 2015-01-30 US US14/610,370 patent/US20150175579A1/en not_active Abandoned
- 2015-01-30 US US14/609,967 patent/US20150182520A1/en not_active Abandoned
- 2015-01-30 US US14/610,465 patent/US20150175581A1/en not_active Abandoned
- 2015-01-30 US US14/610,251 patent/US20150152090A1/en not_active Abandoned
- 2015-01-30 US US14/610,338 patent/US20150140081A1/en not_active Abandoned
- 2015-01-30 US US14/609,743 patent/US20150140075A1/en not_active Abandoned
- 2015-01-30 US US14/610,291 patent/US20150140080A1/en not_active Abandoned
- 2015-01-30 US US14/610,043 patent/US20150140078A1/en not_active Abandoned
- 2015-01-30 US US14/610,346 patent/US20150175578A1/en not_active Abandoned
- 2015-01-30 US US14/610,414 patent/US20150175580A1/en not_active Abandoned
- 2015-01-30 US US14/610,318 patent/US20150175577A1/en not_active Abandoned
- 2015-01-30 US US14/610,182 patent/US20150140079A1/en not_active Abandoned
- 2015-07-09 JP JP2015137500A patent/JP2015187165A/ja not_active Withdrawn
-
2016
- 2016-11-21 US US15/357,237 patent/US20170143690A1/en not_active Abandoned
- 2016-11-30 US US15/364,935 patent/US20170143691A1/en not_active Abandoned
- 2016-12-08 US US15/372,863 patent/US20170143692A1/en not_active Abandoned
- 2016-12-09 US US15/373,604 patent/US20170143693A1/en not_active Abandoned
-
2017
- 2017-02-24 CY CY20171100257T patent/CY1118660T1/el unknown
- 2017-05-18 JP JP2017099005A patent/JP2017141297A/ja not_active Withdrawn
-
2019
- 2019-02-12 JP JP2019022433A patent/JP6816180B2/ja active Active
-
2020
- 2020-02-26 JP JP2020030710A patent/JP2020079312A/ja active Pending
-
2022
- 2022-07-27 US US17/815,256 patent/US20230233551A1/en active Pending